NEW YORK, September 23, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: MannKind Corporation (NASDAQ: MNKD), Novavax
Inc. (NASDAQ: NVAX), Incyte Corporation (NASDAQ: INCY), BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), and Sangamo Biosciences Inc.
(NASDAQ: SGMO). Free research report on MannKind can be accessed at
https://www.erionline.net/MNKD.pdf On Tuesday, September 22, 2015, the NASDAQ Composite
ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average
lost 1.09%, to finish the day at 16,330.47, and the S&P 500
closed at 1,942.74, down 1.23%. The losses were broad based as
eight out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
MannKind Corp.'s stock lost 3.57%, to close the day at
$3.24. The stock recorded a trading
volume of 4.88 million shares, much below its three months average
volume of 5.09 million shares. Over the last one month and over the
past three months, MannKind Corp.'s shares have declined 14.51% and
45.45%, respectively. Furthermore, the stock has plummeted 37.87%
since the start of this year. The company's shares are trading
23.62% below their 50-day moving average. Additionally, MannKind
Corp. has a Relative Strength Index (RSI) of 32.18. Sign up and
read the free notes on MNKD at:
https://www.erionline.net/MNKD.pdf
On Tuesday, shares in Novavax Inc. recorded a trading volume of
4.15 million shares, lower than their three months average volume
of 5.12 million shares. The stock ended the day 1.41% lower at
$9.77. Novavax Inc.'s stock has
plummeted 19.59% in the last one month and 12.06% in the previous
three months. However, the stock has surged 64.76% on YTD basis.
The company is trading above its 200-day moving average by 7.53%.
Furthermore, shares of Novavax Inc. have an RSI of 40.56. The
complimentary notes on NVAX can be downloaded in PDF format at:
https://www.erionline.net/NVAX.pdf
Incyte Corp.'s stock edged 0.74% lower, to close Tuesday's
session at $117.78. The stock
recorded a trading volume of 1.64 million shares, above its three
months average volume of 1.23 million shares. Over the last one
month and the previous three months, Incyte Corp.'s shares have
gained 12.91% and 7.75%, respectively. Additionally, the stock has
surged 61.10% since the start of this year. The company is trading
3.91% and 21.43% above its 50-day and 200-day moving averages,
respectively. Furthermore, Incyte Corp.'s stock traded at a PE
ratio of 2944.50 and has an RSI of 48.64. Register for free on
Equity Research Institute and access the latest research on INCY
at:
https://www.erionline.net/INCY.pdf
BioMarin Pharmaceutical Inc.'s stock finished Tuesday's session
3.37% lower at $117.97. A total of
2.26 million shares were traded, which was above its three months
average volume of 1.22 million shares. Over the last one month and
the previous three months, BioMarin Pharmaceutical Inc.'s shares
have fallen by 6.50% and 15.04%, respectively. However, the stock
has surged 30.50% since the beginning of 2015. The company's shares
are trading below their 50-day and 200-day moving averages by
13.47% and 0.79%, respectively. BioMarin Pharmaceutical Inc.'s
stock has an RSI of 33.99. The complete research on BMRN is
available for free at:
https://www.erionline.net/BMRN.pdf
On Tuesday, shares in Sangamo Biosciences Inc. ended the session
1.27% lower at $6.97. The stock
reported a trading volume of 1.11 million shares, below its three
months average volume of 1.19 million shares. Sangamo Biosciences
Inc.'s shares have plummeted 9.72% in the last one month, 38.54% in
the previous three months and 54.17% on YTD basis. The company is
trading 15.80% below its 50-day moving average and 44.45% below its
200-day moving average. Moreover, shares of Sangamo Biosciences
Inc. have an RSI of 41.20. Free in-depth research on SGMO is
available at:
https://www.erionline.net/SGMO.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net